Phase 3 randomized double-blind trial of BI 456906 in adults with overweight or obesity without type 2 diabetes

Phase 3, randomised, double-blind trial in obesity and Overweight comparing BI 456906 with Placebo (2 arms). Primary endpoints: Percentage change in body weight from baseline to Week 76 and Achievement of body weight reduction ≥5% from baseline to Week 76. Started Jan 2024; status: completed.